RU2272809C2 - Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы - Google Patents

Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы Download PDF

Info

Publication number
RU2272809C2
RU2272809C2 RU2002133470/13A RU2002133470A RU2272809C2 RU 2272809 C2 RU2272809 C2 RU 2272809C2 RU 2002133470/13 A RU2002133470/13 A RU 2002133470/13A RU 2002133470 A RU2002133470 A RU 2002133470A RU 2272809 C2 RU2272809 C2 RU 2272809C2
Authority
RU
Russia
Prior art keywords
antibody
rabies virus
seq
amino acid
cells
Prior art date
Application number
RU2002133470/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2002133470A (ru
Inventor
Дуглас К. ХУПЕР (US)
Дуглас К. ХУПЕР
Бернхард ДИТЦШОЛЬД (US)
Бернхард ДИТЦШОЛЬД
Original Assignee
Томас Джефферсон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Томас Джефферсон Юниверсити filed Critical Томас Джефферсон Юниверсити
Publication of RU2002133470A publication Critical patent/RU2002133470A/ru
Application granted granted Critical
Publication of RU2272809C2 publication Critical patent/RU2272809C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2002133470/13A 2000-05-16 2001-05-04 Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы RU2272809C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20451800P 2000-05-16 2000-05-16
US60/204,518 2000-05-16

Publications (2)

Publication Number Publication Date
RU2002133470A RU2002133470A (ru) 2004-06-10
RU2272809C2 true RU2272809C2 (ru) 2006-03-27

Family

ID=22758233

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002133470/13A RU2272809C2 (ru) 2000-05-16 2001-05-04 Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы

Country Status (9)

Country Link
US (1) US6890532B2 (https=)
EP (1) EP1282703B1 (https=)
JP (1) JP4819285B2 (https=)
AT (1) ATE411387T1 (https=)
CA (1) CA2419148C (https=)
DE (1) DE60136174D1 (https=)
IL (1) IL152825A (https=)
RU (1) RU2272809C2 (https=)
WO (1) WO2001088132A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
WO2003016501A2 (en) * 2001-08-21 2003-02-27 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
WO2004106375A1 (en) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
RS53239B (sr) 2005-02-02 2014-08-29 University Of Massachusetts Humana antitela protiv besnila i njihove upotrebe
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111166877A (zh) * 2019-12-30 2020-05-19 西安回天血液制品有限责任公司 一种狂犬病人免疫球蛋白的制备方法
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
IL89857A0 (en) * 1988-04-07 1989-12-15 Erba Carlo Spa Human monoclonal antibodies specifically recognizing rabies virus hybridoma,cells producing them,pharmaceutical compositions containing them and their production
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEUNG et al., A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus, Journal of virology, Nov.1992, стр.6714-6720. PATERSON et al., Variation in IgG1 heavy chain allotype does not con-tribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies, Immunotechnology, 1998, Jun, 4 (1): стр.37-47. http://ww../query.fcgi&cmd=Retrieve&db=Protein&list_uids=11275302&do pt=GenPep, Submitted 17.05.1999 Masataka Takekoshi. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства

Also Published As

Publication number Publication date
US6890532B2 (en) 2005-05-10
ATE411387T1 (de) 2008-10-15
CA2419148C (en) 2011-07-12
EP1282703A2 (en) 2003-02-12
WO2001088132A2 (en) 2001-11-22
IL152825A0 (en) 2003-06-24
EP1282703B1 (en) 2008-10-15
US20030165507A1 (en) 2003-09-04
DE60136174D1 (de) 2008-11-27
CA2419148A1 (en) 2001-11-22
JP4819285B2 (ja) 2011-11-24
WO2001088132A3 (en) 2002-07-18
IL152825A (en) 2009-07-20
JP2004528803A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
RU2272809C2 (ru) Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы
CN113354729B (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
EP0690132B1 (en) Anti-hiv monoclonal antibody
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
CA2091335A1 (en) Antibodies for treatment and prevention of infection in animals and man
RU2292353C2 (ru) Рекомбинантные антитела и композиции, а также способы их создания и использования
JPWO1994020632A1 (ja) 抗ｈｉｖモノクローナル抗体
CN103221063B (zh) 针对人类巨细胞病毒(cmv)gb蛋白质的高亲和力人类抗体
AU2002332600A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
CN118530348A (zh) 一种广谱中和冠状病毒的抗体及其应用
Hamilton et al. A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections
WO1994028933A1 (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
CN113748203B (zh) 重组经典猪瘟病毒
Cheung et al. A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus
CN110483636B (zh) 人源抗HIVgp120特异性抗体Z166及其应用方法
US7071319B2 (en) Recombinant antibodies, and compositions and methods for making and using the same
JP4263951B2 (ja) イヌ化抗体の作成方法および使用
CN114957479A (zh) 抗H1N1流感病毒双特异性中和抗体Bis-Hu11-1及其应用
RU2793967C1 (ru) Однодоменное антитело ламы Н5 и его производное H5-Fc, специфически связывающие RBD-домен S-белка вируса SARS-CoV-2, обладающие вируснейтрализующей активностью
RU2769223C1 (ru) Средство и способ терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2 на основе рекомбинантного антитела и гуманизированного моноклонального антитела
RU2765731C1 (ru) Гуманизированное моноклональное антитело, специфически связывающиеся с RBD S белка вируса SARS-CoV-2, средство и способ для терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2
HK1071898B (en) Recombinant antibodies, and compositions and methods for making and using the same
US20020115143A1 (en) Rhabdovirus-based vectors to express high levels of functional human antibodies
JPH06506947A (ja) 抗ウィルスハイブリッド抗体
CN120518752A (zh) 同时针对寨卡病毒和乙脑病毒的抗体或抗原结合片段、核酸、重组载体与应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190505